Clinical Trials Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Aug 26, 2024; 12(24): 5534-5541
Published online Aug 26, 2024. doi: 10.12998/wjcc.v12.i24.5534
Effect of dietary with Zhibai dihuang pills and gonadotropin-releasing-hormone-analogue on girls with precocious and rapidly progressive puberty
Xue-Mei Wang, Wei Li, Liu-Qing Yang, Rui Luo, Chen-Chen Zhang
Xue-Mei Wang, Wei Li, Liu-Qing Yang, Rui Luo, Chen-Chen Zhang, Department of Pediatrics, Ma’anshan Maternal and Child Health Hospital, Ma’anshan 243011, Anhui Province, China
Author contributions: Wang XM contributed to the conceptualization, formal analysis, project administration, software, supervision, validation, visualization, writing-original draft, and writing-review & editing of this manuscript; Wang XM and Li W participated in the data curation; Wang XM, Li W, and Yang LQ took part in the investigation and methodology of this manuscript; Luo R and Zhang CC were involved in the resources.
Institutional review board statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by Institutional Review Board of Ma’anshan Maternal and Child Health Hospital.
Clinical trial registration statement: This study was registered at Ma’anshan Maternal and Child Health Hospital clinical trial registry. Hospital Clinical Trial Registry, Registration number: MASSFYBJY-LLWYH26.
Informed consent statement: All the study subjects provided informed consent.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: The data in this study can be obtained from the corresponding author upon reasonable request.
CONSORT 2010 statement: The authors have read the CONSORT 2010 Statement, and the manuscript was prepared and revised according to the CONSORT 2010 Statement.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: Https: //creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xue-Mei Wang, MM, Associate Chief Physician, Department of Pediatrics, Ma’anshan Maternal and Child Health Hospital, No. 446 Jiashan Road, Ma’anshan 243011, Anhui Province, China. xuemeiwang23@163.com
Received: May 31, 2024
Revised: June 24, 2024
Accepted: July 1, 2024
Published online: August 26, 2024
Processing time: 40 Days and 20.8 Hours
Abstract
BACKGROUND

At present, the clinical mechanisms underlying precocious puberty remain unclear, making effective intervention for children experiencing this condition and rapidly progressive puberty essential.

AIM

To explore the effects of Zhibai dihuang pills and gonadotropin-releasing hormone analogue (GnRHa) on growth and ovarian function in girls with precocious puberty.

METHODS

The clinical data of 84 adolescent girls with precocious puberty and rapidly progressive puberty from February 2017 to August 2023 were retrospectively analyzed. Girls were divided into a control group and an observation group, with 42 cases in each group. The control group received diet intervention combined with GnRHa treatment, while the observation group received diet intervention combined with Zhibai dihuang pills + GnRHa treatment. Outcomes such as clinical efficacy, growth indicators, ovarian function, and adverse reactions were compared between the two groups.

RESULTS

The observation group showed superior clinical efficacy compared to the control group (P < 0.05). Prior to the intervention, no significant differences were found in growth or ovarian function between the groups (P > 0.05). Post-intervention, the observation group exhibited significantly lower rates in growth, height, and bone age, along with reduced levels of progesterone, testosterone, estradiol, prolactin, luteinizing hormone, and follicle-stimulating hormone compared to the control group (P < 0.05). The incidence of adverse reactions was similar across both groups (P > 0.05).

CONCLUSION

Combining Zhibai dihuang pills with GnRHa and dietary intervention effectively improves growth, enhances ovarian function, and minimizes adverse reactions in adolescent girls with precocious and rapidly progressive puberty.

Keywords: Zhibai dihuang pills; Gonadotropin-releasing hormone analogue; Dietary intervention; Precocious puberty; Rapidly progressive puberty; Ovarian function

Core Tip: Combining Zhibai dihuang pills with gonadotropin-releasing hormone analogue (GnRHa) and dietary intervention significantly improves growth outcomes and ovarian function in girls with precocious and rapidly progressive puberty. In this study, girls treated with this combination showed lower rates of growth and bone age advancement, along with reduced levels of key hormones, compared to a control group receiving only GnRHa and diet intervention. This study highlighted the enhanced efficacy and safety of the combined treatment and provides a promising intervention for managing precocious puberty.